Ok so I did a quick search on Magnesium and Pain to see if I could pull up anything more than my simple anecdote. Here are a couple abstracts.
P. S. With regards to some of your concerns regarding the psychotic aspects of Ketamine. Might happen with larger doses and without a benzo but I have never seen it with the addition of some Midaz. People just seem happy and comfortable.
http://www.sciencedirect.com/scienc...d=458507&md5=1629185163cf05de48483bb0a64f4c82
The Safety and Efficacy of a Single Dose (500 mg or 1 g) of Intravenous Magnesium Sulfate in Neuropathic Pain Poorly Responsive to Strong Opioid Analgesics in Patients with Cancer
Abstract
Neuropathic pain may respond poorly to morphine and is often difficult to relieve. Recent attention has been drawn to the role of the N-methyl-Image-aspartate (NMDA) receptor in the potentiation of neuropathic pain. Magnesium is known to block the NMDA receptor. It reduces the neuropathic pain response in animals, and attenuates postoperative pain and migraine in humans. We have examined the safety, tolerability, and efficacy of two intravenous doses of magnesium sulfate in 12 patients with neuropathic pain due to malignant infiltration of the brachial or lumbosacral plexus. The first six patients received 500 mg, the remainder 1 g. Apart from a mild feeling of warmth at the time of the injection, both doses were well tolerated. After receiving 500 mg, three patients experienced complete pain relief and two experienced partial pain relief for up to 4 hours duration; pain was unchanged in one patient. After receiving 1 g, one patient experienced complete relief and four experienced partial pain relief of similar duration; pain was unchanged in one patient. Intravenous magnesium sulfate in these doses appears to be safe and well tolerated. A useful analgesic effect may be obtained in some patients and further evaluation is warranted.
http://bja.oxfordjournals.org/cgi/content/full/89/4/594
Evaluation of effects of magnesium sulphate in reducing intraoperative anaesthetic requirements
Background. The present randomized, placebo-controlled, double-blind study was designed to assess the effect of peroperatively administered i.v. magnesium sulphate on anaesthetic and analgesic requirements during total i.v. anaesthesia.
Methods. Eighty-one patients (36 women, 45 men) undergoing elective spinal surgery were included in one of two parallel groups. The magnesium group received magnesium sulphate 30 mg kg1 as a bolus before induction of anaesthesia and 10 mg kg1 h1 by continuous i.v. infusion during the operation period. The same volume of isotonic solution was administered to the control group. Anaesthesia was maintained with propofol (administered according to the bispectral index) and remifentanil (adjusted according to heart rate and arterial blood pressure) infusions.
Results. A significant reduction in hourly propofol consumption was observed with magnesium administration. For example, the mean infusion rate of propofol in the second hour of the operation was 7.09 mg kg1 h1 in the control group vs 4.35 mg kg1 h1 in the magnesium group (P<0.001). The magnesium group required significantly less remifentanil (P<0.001) and vecuronium (P<0.001). No side-effects were observed with magnesium administration.
Conclusion. The administration of magnesium led to a significant reduction in the requirements for anaesthetic drugs during total i.v. anaesthesia with propofol, remifentanil and vecuronium.
http://bja.oxfordjournals.org/cgi/content/full/89/5/711
Efficacy of intravenous magnesium in neuropathic pain
Background. Postherpetic neuralgia is a complication of acute herpes zoster characterized by severe pain and paraesthesia in the skin area affected by the initial infection. There is evidence that the N-methyl-D-aspartate receptor is involved in the development of hypersensitivity states and it is known that magnesium blocks the N-methyl-D-aspartate receptor.
Method. A double-blind, placebo-controlled, cross-over study was conducted in which magnesium sulphate was administered as an i.v. infusion. Spontaneous pain was recorded and qualitative sensory testing with cotton wool was performed in seven patients with postherpetic neuralgia before and after the i.v. administration of either magnesium sulphate 30 mg kg1 or saline.
Results. During the administration, pain scores were significantly lower for magnesium compared with placebo at 20 and 30 min (P=0.016) but not at 10 min. I.V. magnesium sulphate was safe, well-tolerated and effective in patients with postherpetic neuralgia.
Conclusion. The present study supports the concept that the N-methyl-D-aspartate receptor is involved in the control of postherpetic neuralgia.
http://bja.oxfordjournals.org/cgi/content/full/96/4/444
Magnesium moderately decreases remifentanil dosage required for pain management after cardiac surgery{dagger}
Background. Magnesium is a calcium and an NMDA-receptor antagonist and can modify important mechanisms of nociception. We evaluated the co-analgesic effect of magnesium in the postoperative setting after on-pump cardiac surgery.
Methods. Forty patients randomly received either magnesium gluconate as an i.v. bolus of 0.21 mmol kg1 (86.5 mg kg1) followed by a continuous infusion of 0.03 mmol1 kg1 h1 (13.8 mg kg1 h1) or placebo for 12 h after tracheal extubation. After surgery, remifentanil was decreased to 0.05 µg kg1 min1 and titrated according to a pain intensity score (PIS, range 16) in the intubated, awake patient and a VAS scale (range 1100) after extubation. If PIS was ≥3 or VAS ≥30, the infusion was increased by 0.01 µg kg1 min1; if ventilatory frequency was ≤10 min1 it was decreased by the same magnitude.
Results. Magnesium lowered the cumulative remifentanil requirement after surgery (P<0.05). PIS ≥3 was more frequent in the placebo group (P<0.05). Despite increased remifentanil demand, VAS scores were also higher in the placebo group at 8 (2 vs 8) and 9 h after extubation (2 vs 7) (P<0.05). Dose reductions attributable to a ventilatory frequency ≤10 min1 occurred more often in the magnesium group (17 vs 6; P<0.05). However, time to tracheal extubation was not prolonged.
Conclusions. Magnesium gluconate moderately reduced the remifentanil consumption without serious side-effects. The opioid-sparing effect of magnesium may be greater at higher pain intensities and with increased dosages.